Australia's most trusted
source of pharma news
Posted 1 December 2021 AM
Competition for market share in the Covid oral antiviral space is heating up with MSD hitting a speed bump, forced to downgrade the efficacy of Lagevrio, while Pfizer is boosting production for Paxlovid, ahead of what it expects is a surge in demand.
In an interview on CNBC on Monday, Pfizer CEO Albert Bourla confirmed the company had increased planned production from 50 million doses to 80 million doses - confident Paxlovid will maintain high efficacy against Omicron and future variants of Covid.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.